Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

ALEXION 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Alexion Pharmaceuticals, Inc. – (ALXN)

Business Wire January 13, 2017

FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) & Lead Plaintiff Deadline - January 17, 2017

GlobeNewswire January 13, 2017

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN

PR Newswire January 12, 2017

Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)

Business Wire January 9, 2017

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact The Firm

Business Wire January 7, 2017

ALEXION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. – (ALXN)

GlobeNewswire January 6, 2017

Alexion Pharmaceuticals, Gartner, L Brands Inc., Weight Watchers, Zayo Group Holdings Inc. and more offer option-trading opportunities that offer returns of more than 17%

PR Newswire January 6, 2017

FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Business Wire January 6, 2017

ALXN ALERT: Rosen Law Firm Reminds Alexion Pharmaceuticals, Inc. Investors of Important January 17 Deadline in Class Action – ALXN

GlobeNewswire January 5, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  January 5, 2017

25 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  January 5, 2017

Alexion to Present at the 35th Annual J.P. Morgan Healthcare Conference

Business Wire January 5, 2017

Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016

Business Wire January 4, 2017

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Alexion Pharmaceuticals, Inc. To Contact The Firm Before Lead Plaintiff Deadline

PR Newswire January 4, 2017

Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Class Action

Business Wire January 4, 2017

ALEXION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - (ALXN)

PR Newswire January 3, 2017

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc.

Marketwired January 3, 2017

ALXN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alexion Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017

PR Newswire January 3, 2017

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ALXN

GlobeNewswire January 2, 2017

Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Alexion Pharmaceuticals, Inc. and Certain of Its Senior Executives

PR Newswire December 30, 2016